证券之星消息，2月27日南向资金减持13.41万股微创医疗（00853.HK）。近5个交易日中，获南向资金 增持的有3天，累计净增持168.96万股。近20个交易日中，获南向资金增持的有14天，累计净增持 1470.22万股。截至目前，南向资金持有微创医疗（00853.HK）9.26亿股，占公司已发行普通股的 48.28%。 微创医疗科学有限公司是一家主要从事医疗器械的销售、生产、研究及开发（R&D）的投资控股公 司。该公司通过八个分部开展业务。心血管介入业务分部包括植入器械、通路器械等产品。骨科医疗器 械业务分部包括关节重建、脊柱等器械。心律管理（CRM）业务分部包括起搏器、除颤器等器械。大 动脉及外周血管介入业务分部包括"L-REBOA"主动脉阻断球囊等产品。神经介入业务分部包括脑动脉 粥样硬化狭窄、弹簧圈等产品。结构性心脏病业务分部包括经导管主动脉瓣植入术等产品。手术机器人 业务分部从事手术机器人器械的制造及研发。外科医疗器械业务分部从事外科医疗器械的制造及研发。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

微创医疗科学有限公司是一家主要从事医疗器械的销售、生产、研究及开发（R&D）的投资控股公 司。该公司通过八个分部开展业务。心血管介入业务分部包括植入器械、通路器械等产品。骨科医疗器 械业务分部包括关节重建、脊柱等器械。心律管理（CRM）业务分部包括起搏器、除颤器等器械。大 动脉及外周血管介入业务分部包括"L-REBOA"主动脉阻断球囊等产品。神经介入业务分部包括脑动脉 粥样硬化狭窄、弹簧圈等产品。结构性心脏病业务分部包括经导管主动脉瓣植入术等产品。手术机器人 业务分部从事手术机器人器械的制造及研发。外科医疗器械业务分部从事外科医疗器械的制造及研发。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，2月26日南向资金增持161.11万股微创医疗（00853.HK）。近5个交易日中，获南向资金 增持的有4天，累计净增持242.47万股。近20个交易日中，获南向资金增持的有15天，累计净增持1842.8 万股。截至目前，南向资金持有微创医疗（00853.HK）9.26亿股，占公司已发行普通股的48.28%。 ...

Core Viewpoint - Southbound funds increased their holdings in MicroPort Scientific Corporation (00853.HK) by 242,100 shares on February 23, indicating a positive sentiment towards the company despite some fluctuations in the previous trading days [1] Group 1: Southbound Fund Activity - In the last 5 trading days, there were 2 days of net reductions in holdings by southbound funds, totaling a net decrease of 915,800 shares [1] - Over the past 20 trading days, southbound funds increased their holdings on 15 days, with a cumulative net increase of 16,929,900 shares [1] - Currently, southbound funds hold 924 million shares of MicroPort, accounting for 48.21% of the company's total issued ordinary shares [1] Group 2: Company Overview - MicroPort Scientific Corporation is primarily engaged in the sales, production, research, and development of medical devices [1] - The company operates through eight divisions, including cardiovascular intervention, orthopedic medical devices, cardiac rhythm management, vascular intervention, neurointervention, structural heart disease, surgical robotics, and surgical medical devices [1] - Key products include implantable devices, surgical robots, and various instruments for cardiovascular and orthopedic applications [1]

业务进展情况 介入式脑机接口项目已完成技术验证，预计2026年启动首例人体临床试验，2028年提交注册申请，为神 经调控领域创新突破奠定基础。 经济观察网 心玮医疗-B（06609.HK）公布了2026年的经营目标及多项核心业务进展。 公司业绩目标 公司于2026年2月7日公布2026年经营目标，计划全年营收不低于5.4亿元、利润不低于1亿元，凸显对业 绩增长的信心。 产品研发进展 自主研发的自膨式颅内药物洗脱支架注册申请已于2026年1月获国家药监局受理，预计2026年底完成取 证，有望成为全球首款同类产品。同时，弹簧圈等产品预计2026年第一季度获得海外市场认证，加速国 际化布局。 战略推进 公司计划以2025年财务数据于2026年申报科创板上市，目前已进入上市辅导阶段，若成功落地将提升资 本平台流动性。 以上内容基于公开资料整理，不构成投资建议。 ...

Core Insights - Southbound funds increased their holdings in MicroPort Medical (00853.HK) by 1.4415 million shares on February 13, with net increases recorded on 4 out of the last 5 trading days, totaling 676,500 shares [1] - Over the past 20 trading days, there have been net increases on 15 days, amounting to 20.3817 million shares [1] - Currently, southbound funds hold 926 million shares of MicroPort Medical, representing 48.26% of the company's total issued ordinary shares [1] Company Overview - MicroPort Medical Science Co., Ltd. is primarily engaged in the sales, production, research, and development (R&D) of medical devices [1] - The company operates through eight divisions, including: - Cardiovascular Interventional Business: Products include implantable devices and access devices [1] - Orthopedic Medical Devices: Focuses on joint reconstruction and spinal devices [1] - Cardiac Rhythm Management (CRM): Includes pacemakers and defibrillators [1] - Aortic and Peripheral Vascular Interventional Business: Features products like the "L-REBOA" aortic occlusion balloon [1] - Neurointerventional Business: Involves products for carotid artery atherosclerosis and coils [1] - Structural Heart Disease Business: Engages in transcatheter aortic valve implantation [1] - Surgical Robotics Business: Manufactures and develops surgical robotic devices [1] - Surgical Medical Devices Business: Focuses on the manufacturing and R&D of surgical medical devices [1]

Core Viewpoint - Southbound funds have reduced their holdings in MicroPort Scientific Corporation (00853.HK) by 1.72 million shares on February 11, with a total net reduction of 2.70 million shares over the past five trading days [1] Group 1: Shareholding Changes - In the last 20 trading days, southbound funds have increased their holdings on 14 days, resulting in a total net increase of 22.13 million shares [1] - Currently, southbound funds hold 924 million shares of MicroPort, accounting for 48.16% of the company's total issued ordinary shares [1] Group 2: Company Overview - MicroPort Scientific Corporation is primarily engaged in the sales, production, research, and development of medical devices [1] - The company operates through eight divisions, including cardiovascular intervention, orthopedic medical devices, cardiac rhythm management, vascular intervention, neurointervention, structural heart disease, surgical robotics, and surgical medical devices [1]

Summary of the Conference Call for Peijia Medical Company and Industry Overview - **Company**: Peijia Medical - **Industry**: Medical Devices, specifically focusing on TAVR (Transcatheter Aortic Valve Replacement) and neurointerventional products Key Points and Arguments Industry Updates 1. The TAVR industry is projected to grow at a rate of 7-8% by 2025, which is slower than previous expectations of around 10% [3] 2. The overall surgical volume in January showed positive growth, indicating a potential recovery in the TAVR market [3] 3. Price adjustments initiated by the healthcare authorities have led to a more favorable pricing structure for innovative products, allowing for higher price points for new offerings [4][11] Company Performance 1. Peijia Medical reported a surgical volume of nearly 3,900 TAVR procedures, with a growth rate of approximately 15%, which is double the industry average [7] 2. The company’s new 2.5 generation valve has gained significant market acceptance, contributing to a 5% increase in implant volume despite being priced at a premium [7] 3. The company expects to achieve a break-even point in profitability by 2026, driven by the performance of its neurointerventional products and the anticipated growth in TAVR procedures [21][56] Product Developments 1. The company successfully launched its new aortic valve product, which is expected to drive significant revenue growth in 2026 [6] 2. Peijia Medical has submitted registration applications for its mitral valve product in Europe, with expectations for approval by the end of the year [6] 3. The company anticipates that the new mitral valve product will generate substantial revenue, with an estimated 1,000 procedures expected in the first half of 2026 [25] Pricing and Market Strategy 1. The pricing strategy for the new mitral valve product aims to position it at the highest price point among domestic competitors, reflecting its innovative features [24] 2. The company has adopted a more conservative approach to subsidies, focusing on financial profitability rather than aggressive market share expansion [32] 3. The recent price adjustments are expected to enhance patient affordability and increase surgical volumes, despite concerns about reimbursement from healthcare authorities [35][41] Competitive Landscape 1. New entrants in the market are expected to increase competition, but Peijia Medical believes that these companies will require time to establish themselves [50] 2. The company maintains a strong market position, with a market share increase to approximately 26.5%, reflecting a growth of 1-2 percentage points from the previous year [10] Other Important Insights 1. The company is optimistic about the long-term growth potential of the TAVR market, despite current challenges [3] 2. Peijia Medical's strategy emphasizes continuous innovation and product differentiation to maintain a competitive edge in the market [52] 3. The management is focused on balancing immediate profitability with long-term growth objectives, ensuring that investments in R&D continue to drive future success [56]

Group 1 - The core point of the article is that southbound funds have increased their holdings in MicroPort Medical (00853.HK) by 60,000 shares on February 9, 2026, while experiencing a net reduction of 2.5329 million shares over the last five trading days [1] - Over the past 20 trading days, southbound funds have increased their holdings in MicroPort Medical on 13 occasions, with a total net increase of 16.2003 million shares [1] - As of now, southbound funds hold 925 million shares of MicroPort Medical, accounting for 48.23% of the company's total issued ordinary shares [1] Group 2 - The total number of shares held by southbound funds on February 9, 2026, is 925 million, with a change of 60,000 shares, reflecting a change of 0.01% [2] - On February 6, 2026, there was a reduction of 1.5155 million shares, representing a decrease of 0.16% [2] - The company operates in the medical device sector, focusing on sales, production, research, and development through eight divisions, including cardiovascular intervention, orthopedic medical devices, cardiac rhythm management, and surgical robotics [2]

Core Viewpoint - Southbound funds reduced their holdings in MicroPort Scientific Corporation (00853.HK) by 3.83 million shares on February 4, indicating a fluctuation in investor sentiment towards the company [1] Group 1: Southbound Fund Activity - Over the past five trading days, southbound funds increased their holdings on three occasions, with a total net increase of 117,100 shares [1] - In the last twenty trading days, there were fourteen days of net increases, totaling 25.75 million shares [1] - Currently, southbound funds hold 926 million shares of MicroPort, representing a significant portion of the company's issued ordinary shares [1] Group 2: Company Overview - MicroPort Scientific Corporation is primarily engaged in the sales, production, research, and development of medical devices [1] - The company operates through eight divisions, including cardiovascular intervention, orthopedic medical devices, cardiac rhythm management, vascular intervention, neurointervention, structural heart disease, surgical robotics, and surgical medical devices [1]

Core Viewpoint - Southbound funds have significantly increased their holdings in MicroPort Scientific Corporation (00853.HK), indicating strong investor interest and confidence in the company's future prospects [1] Group 1: Southbound Fund Activity - On February 2, southbound funds increased their holdings by 2.0861 million shares of MicroPort Scientific [1] - Over the past five trading days, there have been four days of net increases, totaling 11.0009 million shares [1] - In the last 20 trading days, there were 15 days of net increases, amounting to 32.4178 million shares [1] - Currently, southbound funds hold 928 million shares of MicroPort Scientific, representing a significant portion of the company's issued ordinary shares [1] Group 2: Company Overview - MicroPort Scientific Corporation is primarily engaged in the sales, production, research, and development of medical devices [1] - The company operates through eight divisions, including cardiovascular intervention, orthopedic medical devices, cardiac rhythm management, vascular intervention, neurointervention, structural heart disease, surgical robotics, and surgical medical devices [1] - Key products include implantable devices, surgical robots, and various instruments for cardiovascular and orthopedic applications [1]